RECRUITING

Improving Status Epilepticus Treatment Times

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a stepped-wedge cluster randomized effectiveness-implementation hybrid study aimed at determining the effect of dissemination of a QI bundle on the time to treatment of SE among hospitalized, non-critically ill children. The primary study endpoint is to decrease the time from the SE diagnosis to treatment with the first dose of a benzodiazepine (BZD) as measured during hospitalization, which will decrease chances of morbidity and mortality.

Official Title

Quality Improvement in Time to Treatment of Status Epilepticus

Quick Facts

Study Start:2024-02-01
Study Completion:2027-03-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06194747

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:30 Days to 18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT
Inclusion CriteriaExclusion Criteria
  1. * SE episode occurs in a male or female child aged between \> 30 days to \< 19 years
  2. * Seizures meeting AT LEAST ONE of the following criteria:
  3. 1. continuous clinically apparent seizure lasting greater than 5 minutes
  4. 2. continuous clinically apparent seizure of any duration receiving BZD
  5. 3. repeated seizures without return to neurological baseline within 5 minutes
  1. * SE episode occurs in a child with infantile spasms
  2. * SE episode occurs in a child with electrographic-only seizures without clinical signs other than encephalopathy

Contacts and Locations

Study Contact

Adam Ostendorf, MD
CONTACT
614-722-5145
adam.ostendorf@nationwidechildrens.org

Principal Investigator

Adam Ostendorf, MD
PRINCIPAL_INVESTIGATOR
Nationwide Children's Hospital and The Ohio State University

Study Locations (Sites)

Nationwide Children's Hospital
Columbus, Ohio, 43205
United States

Collaborators and Investigators

Sponsor: Nationwide Children's Hospital

  • Adam Ostendorf, MD, PRINCIPAL_INVESTIGATOR, Nationwide Children's Hospital and The Ohio State University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-02-01
Study Completion Date2027-03-31

Study Record Updates

Study Start Date2024-02-01
Study Completion Date2027-03-31

Terms related to this study

Keywords Provided by Researchers

  • Status Epilepticus
  • Quality Improvement
  • Interventions

Additional Relevant MeSH Terms

  • Status Epilepticus